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Abstract
In humans, plasma amino acid concentrations of branched-chain amino acids (BCAA) and aromatic amino acids (AAA)
increase in states of obesity, insulin resistance and diabetes. We here assessed whether these putative biomarkers can also
be identified in two different obesity and diabetic mouse models. C57BL/6 mice with diet-induced obesity (DIO) mimic the
metabolic impairments of obesity in humans characterized by hyperglycemia, hyperinsulinemia and hepatic triglyceride
accumulation. Mice treated with streptozotocin (STZ) to induce insulin deficiency were used as a type 1 diabetes model.
Plasma amino acid profiling of two high fat (HF) feeding trials revealed that citrulline and ornithine concentrations are
elevated in obese mice, while systemic arginine bioavailability (ratio of plasma arginine to ornithine + citrulline) is reduced.
In skeletal muscle, HF feeding induced a reduction of arginine levels while citrulline levels were elevated. However, arginine
or citrulline remained unchanged in their key metabolic organs, intestine and kidney. Moreover, the intestinal conversion of
labeled arginine to ornithine and citrulline in vitro remained unaffected by HF feeding excluding the intestine as prime site
of these alterations. In liver, citrulline is mainly derived from ornithine in the urea cycle and DIO mice displayed reduced
hepatic ornithine levels. Since both amino acids share an antiport mechanism for mitochondrial import and export, elevated
plasma citrulline may indicate impaired hepatic amino acid handling in DIO mice. In the insulin deficient mice, plasma
citrulline and ornithine levels also increased and additionally these animals displayed elevated BCAA and AAA levels like
insulin resistant and diabetic patients. Therefore, type 1 diabetic mice but not DIO mice show the ‘‘diabetic fingerprint’’ of
plasma amino acid changes observed in humans. Additionally, citrulline may serve as an early indicator of the obesity-
dependent metabolic impairments.
Citation: Sailer M, Dahlhoff C, Giesbertz P, Eidens MK, de Wit N, et al. (2013) Increased Plasma Citrulline in Mice Marks Diet-Induced Obesity and May Predict the
Development of the Metabolic Syndrome. PLoS ONE 8(5): e63950. doi:10.1371/journal.pone.0063950
Editor: Mihai Covasa, INRA, France
Received October 19, 2012; Accepted April 10, 2013; Published May 14, 2013
Copyright:  2013 Sailer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by the European Nutrigenomics Organisation, an EC-funded Network of Excellence (Grant No. FOOD-2004-506360). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hannelore.daniel@tum.de
Introduction
The metabolic syndrome is characterized by central obesity,
hyperglycemia, dyslipidemia and insulin resistance (IR) associated
with an increased risk for the development of cardiovascular
disease and type 2 diabetes mellitus (T2DM). A blunted response
of peripheral tissues to insulin action leads to disturbances of
carbohydrate, amino acid, and lipid metabolism. Insulin-mediated
glucose uptake into skeletal muscle and adipose tissue is impaired
and the subsequent hyperglycemia is considered to further
promote IR and T2DM. Reduced insulin-mediated suppression
of lipolysis and lipid accumulation in non-adipose tissue plays a
pivotal role in the development of IR. Insulin also regulates
protein biosynthesis in a tissue-specific manner [1] and activates
amino acid transporters in skeletal muscle [2–4]. Dietary amino
acids can stimulate secretion of the incretins gastric inhibitory
polypeptide and glucagon-like peptide-1 from intestinal endocrine
cells, which further enhance glucose-mediated insulin release from
pancreatic b-cells [5,6]. Selected amino acids can also directly
elicit insulin secretion [7,8]. By activating the mammalian target of
rapamycin/raptor pathway, amino acids stimulate S6 kinase 1
leading to an inhibition of insulin signaling by a negative feedback
[9–11] and IR in turn also affects protein metabolism [12,13].
Thus, it is not surprising that recent metabolomics studies in obese
and diabetic subjects report significant alterations in plasma amino
acid levels, particularly elevations of BCAA and AAA [14,15].
These data confirm essentially the pioneering work of Felig et al.
who showed increased plasma levels of valine, leucine, isoleucine,
tyrosine, and phenylalanine in obese subjects [16]. Similar changes
in plasma BCAA are found in Zucker diabetic fatty rats [17], in
leptin-deficient ob/ob mice [18], in AKITA mice as a model for
type 1 diabetes [19], and in type 1 diabetic patients [20].
DIO in mice is frequently used as a model for metabolic
impairments in humans characterized by hyperglycemia, hyper-
insulinemia and non-alcoholic fatty liver disease. To assess
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whether such mice produce the same changes in the plasma amino
acid profile as found in obese humans and in subjects with IR and
T2DM, we analyzed plasma and tissue samples from C57BL/6
mice fed HF diets for 12 weeks. These mice developed
hyperglycemia and showed increased hepatic triglyceride levels
[21,22]. Amino acids and derivatives were quantified using a
targeted liquid chromatography-tandem mass spectroscopy (LC-
MS/MS) approach with iTRAQ-labeling. We found that mice
with DIO possess increased plasma citrulline and ornithine levels
compared to control (C) animals. Similar increases of these amino
acids were also registered in C57BL/6 mice with insulin-deficiency
induced by STZ treatment. In addition, STZ-treated mice, but not
DIO mice displayed the expected increases of BCAA and AAA
levels in plasma.
Results
HF feeding induced changes in plasma
Animals receiving the HF diets gained significantly more
weight, displayed hyperglycemia and accumulated more hepatic
triglycerides as compared to C animals (Table 1). Whereas plasma
concentrations of BCAA and phenylalanine increase in human
obesity and T2DM, levels remained unaltered in obese mice and
tyrosine levels were significantly elevated only in study 1 (Table 2).
Although we observed changes over time, when plasma amino
acid concentrations were monitored every second week in study 1,
BCAA, phenylalanine, and tyrosine displayed no time x diet
interaction based on two-way ANOVA as shown for the BCAA
(Figure 1). However, all animals on HF diets displayed increased
plasma citrulline and ornithine concentrations after 12 weeks
(Table 2) and significant cross-correlations (study 1: r = 0.7,
p,0.001; study 2: r = 0.68, p=0.004) between citrulline and
ornithine were observed. Moreover, as depicted in Figure 1,
citrulline also showed a significant two-way interaction for
time6diet (p = 0.002) in study 1. In both feeding trials, the changes
in citrulline and ornithine concentrations resulted in a diminished
systemic arginine bioavailability [23,24] defined by the ratio of
plasma arginine to ornithine and citrulline levels (Figure 2) while
arginine levels were increased in HF animals of study 1 (Table 2).
In addition, analysis of plasma amino acids in HF animals
revealed reduced levels of a-aminoadipate in both studies and of
hydroxyproline in study 1. Furthermore, increased plasma levels
were found for ethanolamine and glutamine in study 1 and for
asparagine, serine, and 3-methyl-histidine in study 2. Yet,
irrespective of the different dietary fat content (45 energy% in
study 1 and 60 energy% in study 2) and fat source (palm oil in
study 1 and soybean oil and beef tallow in study 2), the majority of
plasma amino acid levels (around 70% in study 1 and 79% in
study 2) remained unchanged when compared to lean C mice
(data provided in Table S1 and S2).
Citrulline and ornithine in small intestine and kidney
A major source of systemic citrulline is the intestine. Here it can
be produced from either arginine or glutamine. Previous
transcriptome profiling of small intestinal tissue samples from
study 1 [25] revealed that the mRNA levels of carbamoyl-
phosphate synthetase 1 and arginase type II increased significantly
(2.2-fold and 1.24-fold, respectively) in animals on HF diets. In
particular the increase in arginase type II suggested that intestinal
ornithine production from arginine could be increased. In
assessing whether the intestine indeed contributes to the increased
systemic ornithine and citrulline levels, we employed the everted
gut sac technique with jejunal tissues of mice after 12 weeks of
feeding C or HF diets and determined the conversion rate of
13C15N-arginine provided in the luminal solution to either
ornithine or citrulline by LC-MS/MS analysis. However, no
significant differences were found in arginine conversion which
accounted in case of ornithine to 2.4861.08 mmol/g protein in
tissues of C mice and 2.6161.66 mmol/g protein in tissues of HF
mice and in case of citrulline to 1.3460.48 mmol/g protein in
tissues of C mice and 1.5960.80 mmol/g protein in tissues of HF
mice (ornithine: p=0.762, citrulline: p=0.206).
Citrulline produced in the intestine can be reconverted to
arginine in the kidney. We therefore also determined the amino
acid levels in intestine (data provided in Table S3) and kidney (data
provided in Table S4) in study 2 but no differences in the tissue
levels of citrulline, ornithine and arginine in these two organs were
observed. Only the levels of argininosuccinate were found to be
reduced in the small intestine (Table 3).
Effect of HF feeding on hepatic and skeletal muscle
amino acids
In contrast to kidney and intestine, hepatic amino acid
concentrations in both HF feeding trials displayed significant
differences in a variety of amino acids. In study 1, 65% of the
quantified amino acids were altered significantly, whereas in study
2, 58% of the quantified amino acids changed significantly.
Fourteen amino acids displayed similar changes in both feeding
trials (data provided in Table S5 and S6). However, the sum of all
amino acids in liver remained unchanged (Table 4). Considering
the amino acids involved in the urea cycle metabolism, animals on
HF diets displayed significantly lower ornithine levels compared to
mice on a C diet, while citrulline levels remained unchanged
(Table 4). Moreover, Pearson correlation analysis revealed an
association between hepatic ornithine levels and plasma citrulline
concentrations (Figure 3). Hepatic contents of glucogenic amino
acids (GAA) did not differ between the dietary groups in both
feeding trials. However, when the high abundant amino acids
alanine (Ala) and glutamine (Gln) were omitted, the remaining
glucogenic amino acids ‘GAA-(Ala+Gln)’ displayed reduced levels
in HF animals compared to C animals (Table 4). These levels
again correlated with hepatic ornithine concentrations (Figure 4),
which suggests an interrelationship between these amino acids in
hepatic metabolism. In addition, DIO mice showed diminished
hepatic concentrations of BCAA, AAA, essential amino acids
(p=0.051 for study 1) as well as of ketogenic amino acids (Table 4).
Analysis of skeletal muscle amino acid levels (data provided in
Table S7) revealed that in DIO mice citrulline concentrations
were increased (C: 2.5560.30 mmol/g protein vs. HF:
3.0760.43 mmol/g protein, p=0.012), while arginine concentra-
tions were reduced (C: 4.8660.84 mmol/g protein vs. HF:
3.8760.72 mmol/g protein, p=0.020) and ornithine concentra-
tions remained unchanged (C: 0.8660.19 mmol/g protein vs. HF:
0.8760.19 mmol/g protein, p=0.914). These changes however
resulted in diminished arginine bioavailability in skeletal muscle
(C: 1.4360.25 vs. HF: 0.9960.15, p,0.001) and a significant
association was found between citrulline levels in plasma and
skeletal muscle (r = 0.61, p=0.012). Furthermore, in skeletal
muscle essential amino acids were reduced (C:
52.6565.19 mmol/g protein vs. HF: 46.465.03 mmol/g protein,
p = 0.024) and ketogenic amino acids also declined significantly (C:
24.2464.32 mmol/g protein vs. HF: 17.8862.67 mmol/g protein,
p = 0.003).
Plasma amino acids in the insulin-deficient state
To compare the effects of such diet-induced metabolic
perturbations with the effects in an insulin-deficient diabetic
condition, we used a type 1 diabetes model by treating C57BL/6
Plasma Citrulline in Diet-Induced Obese Mice
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mice with STZ. The loss of insulin led to a marked reduction in
body weight and an almost 4-fold increase in blood glucose
concentration 5 days after STZ treatment (Table 1). Plasma amino
acid profiling in these mice revealed a prominent increase of
valine, leucine, and isoleucine levels. The aromatic amino acids
phenylalanine and tyrosine, as well as the total sum of all measured
amino acids also showed elevated levels (Table 2 and Table S8). In
addition, the diabetic mice displayed a 3-fold elevated concentra-
tion of a-aminobutyrate and increased ornithine and citrulline
levels compared to C animals (Table 2). Like for DIO mice, in the
insulin-deficient mice systemic arginine bioavailability was dimin-
ished compared to C mice (C: 1.0160.11 vs. STZ: 0.5960.08,
p,0.001) and a high correlation was found between plasma
ornithine and citrulline levels (r = 0.89, p,0.001). Thus, citrulline
and ornithine showed similar changes in both models while only in
the type 1 diabetes model BCAA, phenylalanine and tyrosine
levels increased in plasma.
Discussion
Various metabolomics approaches in humans have shown
increased plasma amino acid levels (mainly BCAA and AAA) in
states of obesity, IR and T2DM. Additionally, plasma concentra-
tions of free fatty acids and ketone bodies have as well been
identified as strongly associated with the obese and diabetic state
[14–16,26,27]. We here describe that similar changes in plasma
amino acids can be observed in a type 1 diabetic mouse model, but
not in DIO models that are used to simulate the metabolic
syndrome associated with hyperglycemia, hyperinsulinemia and
non-alcoholic fatty liver disease.
Although all mice fed a HF diet for 12 weeks displayed
hyperglycemia and increased liver triglyceride content, common
significant diet-induced changes in plasma amino acid levels were
only found for citrulline and ornithine. Both feeding trials
employed diets that differed in composition by total fat content
and dietary fat source and additionally the nutritional state varied
as mice were either fasted (study 1) or non-fasted (study 2) when
they were sacrificed. Therefore, the consistent changes found in
plasma citrulline and ornithine levels suggest those to arise from
the metabolic condition and not from dietary differences. Despite
the fact that other changes in plasma amino acids were observed
over time, neither plasma BCAA nor phenylalanine levels revealed
significant differences between HF and C animals after 12 weeks.
The increases found here in plasma citrulline as associated with
DIO are however consistent with data reported by Connor et al. in
leptin receptor-deficient db/db mice [28] and those reported by
She et al. in leptin-deficient ob/ob mice [18]. When in mice on a
HF diet a part of the protein was replaced by ketogenic essential
amino acids, animals gained less body weight, had improved blood
glucose and insulin concentrations, and displayed lower plasma
citrulline levels after 8 weeks of intervention compared to mice on
a normal HF diet [29]. This is in support of our findings with a
close association between the obesity state and plasma citrulline
levels. Like for study 1, a time-dependent raise of plasma citrulline
concentration was also shown in AKITA type 1 diabetic mice
[19]. In contrast, findings in human studies are far less consistent.
While increased plasma citrulline concentrations were reported
recently in severely obese subjects with hyperglycemia and were
strongly associated with elevated levels of glycosylated hemoglobin
[30], other studies reported a small decrease in plasma citrulline or
Figure 1. Time-courses of selected plasma amino acid concentrations during 12 weeks of HF dietary intervention in study 1. Grey
and black lines represent C (n = 12) and HF animals (n = 12) feeding either a 10 energy% C diet or a 45 energy% HF diet for 12 weeks, respectively.
Mice were fasted for 5 hours before they were sacrificed. Data are presented as mean 6 SD. Asterisks indicate statistical significance based on two-
way ANOVA followed by pairwise comparison using Tukey test. *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0063950.g001
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unaltered levels in obese subjects [31] and type 1 diabetic patients
[32].
What makes citrulline unique is a distinct inter-organ cycle that
is thought to ensure a constant systemic arginine concentration
[33]. As citrulline can be derived from arginine via nitric oxide
(NO)-synthase, a systemic arginine bioavailability index (ratio of
arginine to sum of ornithine and citrulline) is frequently
determined as a surrogate of a reduced NO synthesis capacity
[23,24,34,35]. In our DIO mice and the type 1 diabetic mice, a
diminished systemic arginine bioavailability was consistently
found. This finding matches with reports of a reduced arginine
bioavailability in apoE2/2 mice fed a HF diet and in C57BL/6
mice supplied with a high-cholesterol diet [23]. Humans with type
2 diabetes also display a reduced arginine bioavailability index
[34,35] associated with endothelial dysfunction and the progres-
sion of cardiovascular diseases. Systemic arginine is mainly derived
from kidneys by re-conversion of citrulline which originates mainly
from the intestine. Precursors of intestinal citrulline are either
dietary arginine or endogenous glutamine [36]. Systemic increases
in citrulline levels as observed in DIO and type 1 diabetic mice
could therefore originate from either an increased intestinal
production or a reduced conversion of citrulline to arginine in
kidney. Our stable isotope study with isolated intestinal tissues
revealed that neither ornithine nor citrulline production from
Figure 2. HF intervention reduced systemic arginine bioavail-
ability obtained by the ratio of plasma arginine to ornithine +
citrulline. In study 1, mice (n = 12 per group) were either fed a C diet
(10 energy% of fat) or a HF diet (45 energy% of fat). In study 2, mice
were either fed a C diet (11 energy% of fat, n = 9) or a HF diet (60
energy% of fat, n = 8). After 12 weeks of dietary intervention, mice were
sacrificied. Data are presented as mean 6 SD. Open bars represent C
mice, grey bar represent HF mice. P-value obtained by unpaired
Student’s t-test.
doi:10.1371/journal.pone.0063950.g002
Table 1. Phenotypic parameters of DIO mice after 12 weeks of HF feeding and of STZ-induced diabetic mice.
Study Parameter Change C HF/STZ p-value
study 1 Body weight (g) q 28.5361.53 38.7462.49 ,0.001
Blood glucose (mM) q 10.3961.05 13.1360.65 ,0.001
Liver triglycerides (mg/g protein) q 363.926103.37 635.946191.21 ,0.001
study 2 Body weight (g) q 32.1461.83 42.4864.32 ,0.001
Blood glucose (mM)
$ q 7.6060.70 9.5360.86 ,0.001
Liver triglycerides (mg/g protein) q 221.93640.33 707.986251.94 ,0.001
STZ study Body weight (g) Q 28.0162.76 23.2261.99 ,0.001
Blood glucose (mM) q 6.0660.50 23.8063.60 ,0.001
Liver triglycerides (mg/g protein) - ND ND -
In study 1, mice (n = 12 per group) were either fed a C diet (10 energy% of fat) or a HF diet (45 energy% of fat) for 12 weeks. In study 2, mice were either fed a C diet (11
energy% of fat, n = 9) or a HF diet (60 energy% of fat, n = 8) for 12 weeks. For the STZ-study, parameters were measured five days after mice (n = 10 per group) received a
single intraperitoneal injection of STZ (180 mg/kg bodyweight) in 0.1 M citrate buffer or 0.1 M citrate buffer alone (C group).
Data are presented as mean 6 SD. P-value obtained by unpaired Student’s t-test.
$
measured after 11 weeks of HF feeding. ND: not determined.
doi:10.1371/journal.pone.0063950.t001
Table 2. Fold-changes of selected plasma amino acids in DIO
mice after 12 weeks of HF feeding and STZ-induced diabetic
mice.
study 1 study 2 STZ study
Amino acid FC p-value FC p-value FC p-value
Valine 1.04 0.498 0.9 0.205 1.65 0.007
Leucine 1.01 0.916 0.91 0.309 1.71 0.004
Isoleucine 1.01 0.848 0.95 0.510 1.58 0.006
Arginine 1.15 0.007 0.93 0.419 0.92 0.507
Citrulline 1.34 ,0.001 1.27 0.015 1.39 0.010
Ornithine 1.24 ,0.001 1.50 0.004 1.84 0.011
a-aminobutyrate 0.85 0.252 0.80 0.079 2.97 0.015
Tyrosine 1.23 0.009 1.06 0.557 1.46 0.026
Phenylalanine 1.03 0.423 0.96 0.624 1.52 0.020
Sum 1.05 0.166 1.09 0.127 1.32 0.029
In study 1, mice (n = 12 per group) were either fed a C diet (10 energy% of fat)
or a HF diet (45 energy% of fat) for 12 weeks. In study 2, mice were either fed a
C diet (11 energy% of fat, n = 9) or a HF diet (60 energy% of fat, n = 7) for 12
weeks. For the STZ-study, parameters were measured five days after mice
(n = 10 per group) received a single intraperitoneal injection of STZ (180 mg/kg
bodyweight) in 0.1 M citrate buffer or 0.1 M citrate buffer alone (C group).
FC: fold-change (HF group/C group or STZ group/C group). P-value obtained by
unpaired Student’s t-test.
doi:10.1371/journal.pone.0063950.t002
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luminally supplied arginine was altered in DIO animals. Although
this may not relate to the in vivo condition, intestinal arginine
extraction is known to depend on the total protein supply and
increases in states of protein starvation but not in response to over-
nutrition [37,38]. The second source of systemic citrulline is
endogenous glutamine. Whether the conversion of glutamine to
citrulline in the intestine is increased in the DIO state is currently
not known and deserves additional studies. As kidney is the prime
tissue for systemic arginine levels, it is not surprising that elevated
plasma citrulline levels also occur in states of renal insufficiency
and proximal tubular dysfunction as shown in rats [39] and in
humans with renal failure [40]. It however appears unlikely that a
renal dysfunction may have caused the elevation in plasma
citrulline in DIO mice since those changes occurred as early as 2
weeks after feeding the HF diet. Moreover, amino acid profiling of
renal and intestinal tissues revealed a reduction of argininosucci-
nate levels in the intestine, but no differences were found for
citrulline, ornithine, or arginine levels in DIO mice in either tissue.
In contrast to kidney and intestine, skeletal muscle displayed an
increase in citrulline and a reduction in arginine levels and thus a
reduced arginine bioavailability. Although muscle may not be
considered as a prime organ in arginine and citrulline metabolism,
it has been shown that palmitic acid enhances NO production in
rat skeletal muscle cells [41] and that mice lacking the inducible
NO-synthase in skeletal muscle are protected from HF induced
insulin resistance [42]. With the association between plasma and
skeletal muscle citrulline levels found here in DIO mice, it is
tempting to speculate that muscle citrulline could also contribute
to the observed plasma increases.
Citrulline is also a product of the urea cycle in liver. Although
animal experiments [36] suggested that liver does not extract
systemic citrulline, human studies have demonstrated that there is
a significant net uptake of circulating citrulline into hepatocytes
[43]. This finding is in contrast to stable isotope tracer studies in
rat liver that demonstrated even a hepatic citrulline release from
labeled glutamine as a precursor [44]. When liver samples in our
DIO mice were profiled for changes in amino acids, significant
alterations in a variety of amino acids including ornithine but not
citrulline were observed. Arginine was below detection limits.
Interestingly, in both HF feeding trials liver ornithine levels
correlated with plasma citrulline levels. Moreover, liver ornithine
status correlated with the levels of glucogenic amino acids, but
only when alanine and glutamine were not taken into account.
These two amino acids are of course important precursors of
hepatic de novo glucose production but their high levels appear to
mask underlying alterations in other glucogenic amino acids that
link to changes in ornithine concentrations. HF feeding in mice
and rats has been shown to enhance hepatic glucose production
[45,46] and the reduced levels of glucogenic amino acids other
than glutamine and alanine may therefore be indicative for an
increased utilization for gluconeogenesis. The inverse relationship
found between hepatic ornithine and systemic citrulline levels is of
course intriguing. During the urea cycle ornithine has to pass from
the cytoplasm, where it is formed, to the mitochondrial matrix,
Table 3. Fold-changes of selected amino acids in small
intestine and kidney in DIO mice after 12 weeks of HF feeding.
Small intestine Kidney
Amino acid FC p-value FC p-value
Citrulline 1.21 0.091 1.14 0.207
Ornithine 1.09 0.317 1.19 0.276
Arginine 0.99 0.963 0.93 0.420
Argininosuccinate 0.61 0.023 ND -
Sum 0.98 0.795 0.93 0.417
Amino acids of small intestine and kidney were measured via LC-MS/MS after 12
weeks dietary intervention, when mice were either fed a C diet (11 energy% of
fat, n = 9) or a HF diet (60 energy% of fat, n = 8) in study 2.
FC: fold-change (HF group/C group). P-value obtained by unpaired Student’s
t-test. Abbreviation: >ND, not detectable.
doi:10.1371/journal.pone.0063950.t003
Figure 3. Pearson correlation between concentrations of
plasma citrulline and liver ornithine. Mice were fed either a C
(10 energy% or 11 energy% of fat) or a HF (45 energy% or 60 energy%
of fat) diet for 12 weeks. Black triangles represent C mice (n = 21), grey
squares HF mice (n = 19). Abbreviations: Cit, citrulline; Orn, ornithine.
doi:10.1371/journal.pone.0063950.g003
Figure 4. Pearson correlation between concentrations of liver
‘GAA–(Ala+Gln)’ and liver ornithine. Mice were fed either a C (10
energy% or 11 energy% of fat) or a HF (45 energy% or 60 energy% of
fat) diet for 12 weeks. Black triangles represent C mice (n = 21), grey
squares HF mice (n = 20). Abbreviations: Ala, alanine; GAA, glucogenic
amino acids; Gln, glutamine; Orn, ornithine.
doi:10.1371/journal.pone.0063950.g004
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where it is carbamylated. The resulting citrulline must then pass
from the matrix to the cytoplasm before being converted to
arginine. This bidirectional transport seems to be mediated by an
ornithine/citrulline exchanger which is coupled to proton
movement to balance charge differences between the substrates
[47]. There is evidence that ornithine transport into and release
from hepatocytes involves a low affinity, high capacity transport
system [48], whereas the transporter(s) responsible for hepatic
citrulline uptake and release are essentially unknown. In rat aortic
smooth muscle cells, Na+-dependent and Na+-independent citrul-
line transport systems could be shown, suggesting systems N and L
like activity [49]. In contrast to the system L-transporter LAT1
which seems to be positively regulated by insulin [50], the
expression of the Na+-dependent system N transporter SNAT3 is
reduced when mouse hepatocytes were chronically treated with
insulin [51]. The increase in plasma citrulline levels in DIO mice
could therefore arise from a reduction in SNAT3 transport activity
although its involvement in hepatic citrulline transport remains to
be determined. That the changes in systemic citrulline levels are
related to insulin action is supported by the observed increase in
plasma citrulline and ornithine levels also in the type 1 diabetic
mice. As liver tissues in DIO models show impaired insulin
responses, the changes in plasma citrulline and ornithine may
serve as a surrogate marker of this hepatic perturbation.
In contrast to the DIO mice, type 1 diabetic mice displayed
significantly increased plasma BCAA levels and tyrosine and
phenylalanine were elevated as well. The changes in BCAA and
citrulline levels are very similar to those reported in AKITA mice
as another type 1 diabetes model [19] and mimic the findings in
diabetic humans [15,52]. What causes these changes in the BCAA
and AAA in diabetic states is currently not understood. The prime
organ in BCAA catabolism is the skeletal muscle and under fasting
conditions the release of BCAA and other amino acids from
muscle is increased [53]. There is now growing evidence that IR
and a diabetic state display plasma metabolome changes
reminiscent of those observed in healthy volunteers under
extended fasting conditions [54]. Fasting causes increased rates
of lipolysis and proteolysis with concomitant elevations of plasma
free fatty acids and amino acids. The almost 3-fold increase in a-
aminobutyrate levels in type 1 diabetic mice may also serve as an
indicator of the increased protein breakdown and amino acid
utilization in insulin-deficiency as a-aminobutyrate is a product of
threonine and methionine catabolism [55,56]. Of note, the most
discriminative marker of a diabetic state in humans found so far is
2-OH-butyrate which derives from the same metabolic pathways
[26].
In summary, we demonstrate increased plasma citrulline levels
when mice progress into an obese state associated with hypergly-
cemia and development of non-alcoholic fatty liver disease. These
changes translate into a decreased systemic arginine bioavailability
that may affect the capacity to produce NO. Tissue profiling
revealed major changes in hepatic amino acid levels in DIO mice.
Changes in selected liver amino acids but also skeletal muscle
arginine and citrulline levels could be correlated with elevated
plasma citrulline levels. Type 1 diabetic mice showed similar
increases in plasma citrulline and ornithine and reduced arginine
bioavailability as DIO mice, but in addition they displayed all
other alterations in plasma amino acids reported for humans with
IR and diabetes such as elevated BCAA, tyrosine, and phenylal-
anine levels. Despite the fact that DIO C57BL/6 mice do not
produce the characteristic plasma amino acid changes as in
humans with IR and diabetes, increases of plasma citrulline follow
closely obesity development and may therefore be predictive for
the metabolic syndrome.
Materials and Methods
Ethic statements and mouse studies
HF Study 1. As described previously [21,22], this study was
part of the Proof of principle package of the European
Nutrigenomics Organisation. All procedures were performed in
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals at Wageningen University. The
study was approved by the Ethical Committee on animal testing of
Wageningen University (Study number 2007118.b). At the age of
12 weeks, 24 male C57BL/6J mice were fed a low-fat diet (10% of
energy obtained from fat) as a run-in period for four weeks. The
mice were then divided into two groups (n = 12) and maintained
either on the C (low-fat) diet or received a HF diet (45% of energy
obtained from fat). Diets contained palm oil as the main fat source
and were based upon Research Diets formulas (www.
researchdiets.com; D12450B/D12451). Throughout the feeding
trial the mice had ad libitum access to food and water. Body weight
and food intake were monitored weekly [22]. Every second week,
plasma was collected into EDTA-coated tubes by puncture of the
retro-orbital sinus. After twelve weeks, the mice were fasted for five
hours, followed by plasma collection under anaesthesia using a
mixture of isoflurane (1.5%), nitrous oxide (70%), and oxygen
(30%). Mice were then sacrificed by cervical dislocation and the
liver was sampled for amino acid analysis. Samples were frozen in
liquid nitrogen and stored at 280uC. Blood glucose levels were
measured after sacrifice using an Accu-Check glucose meter
(Roche Diagnostics, Almere, The Netherlands) [22].
HF study 2. This study was performed in C57BL/6N mice.
All procedures were conducted according to the German
guidelines for animal care and approved by the state of Bavaria
(Regierung von Oberbayern) ethics committee (Reference number
209.1/211-2531-41/03). Animals were purchased from Charles
River Laboratories at the age of eight weeks and maintained at a
12 h light/dark cycle with ad libitum access to food and water. At
the age of ten weeks, the mice were randomized into two groups
Table 4. Fold-changes of selected (groups of) amino acids in
liver in DIO mice after 12 weeks of HF feeding.
study 1 study 2
Amino acid FC p-value FC p-value
Citrulline 1.30 0.058 0.84 0.128
Ornithine 0.74 0.003 0.74 0.004
Arginine ND - ND -
Glucogenic AA 1.02 0.670 0.98 0.766
GAA-(Ala+Gln) 0.89 0.008 0.85 0.009
Ketogenic AA 0.83 0.006 0.80 0.004
BCAA 0.86 0.033 0.77 0.003
Aromatic AA 0.83 0.019 0.85 0.015
Essential AA 0.91 0.051 0.83 0.007
Sum 1.06 0.126 1.01 0.820
Mice (n = 12 per group) were either fed a C diet (10 energy% of fat) or a HF diet
(45 energy% of fat) in study 1. In study 2, mice received either a C diet (11
energy% of fat, n = 9) or a HF diet (60 energy% of fat, n = 8).
Abbreviations: AA, amino acids; GAA, glucogenic amino acids; Ala, alanine; Gln,
glutamine; BCAA, branched-chain amino acids; FC, fold-change (HF group/C
group); ND, not detectable. P-value obtained by unpaired Student’s t-test.
doi:10.1371/journal.pone.0063950.t004
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(n = 9): a C diet (11% of energy obtained from fat, Ssniff GmbH,
Soest, Germany; E15000-04) or a HF diet (60% of energy
obtained from fat, Ssniff GmbH, Soest, Germany; E15741-34)
group. After 11 weeks of dietary intervention, mice were fasted for
6 hours and blood glucose was measured using a blood spot of the
tail vein and the Accu-Check glucose meter. After 12 weeks, non-
fasted mice were anaesthetized using isoflurane and blood was
collected by puncture of the retro-orbital sinus into lithium
heparin coated tubes. After sacrificing the mice by cervical
dislocation, the small intestine was removed and used for gut sac
experiments as described below. For amino acid analysis liver,
small intestine, kidney, and skeletal muscle tissues were snap
frozen in liquid nitrogen and stored at 280uC.
The nutrient compositions of the diets used in the two feeding
trials are displayed in Table 5.
Type 1 diabetic mice. Twelve weeks old male C57BL/6J
mice were maintained at 12:12 h light/dark cycle with food and
water ad libitum. Mice received a standard laboratory chow diet
(Ssniff GmbH, Soest, Germany; V1534) and mice were kept in
pairs. All experiments were conducted according to the German
guidelines for animal care and approved by the state of Bavaria
(Regierung von Oberbayern) ethics committee (Reference num-
ber: 55.2.1-54-2532-22-11). The STZ-treated group (n= 10)
received a single intraperitoneal dose of 180 mg/kg body weight
STZ (Sigma Aldrich, USA) in 0.1 M citric acid buffer (pH=4.5).
C mice (n = 10) were injected intraperitoneally with 0.1 M citric
acid buffer (pH=4.5) alone. After 5 days, blood glucose was
measured using a blood spot of the tail vein and the Accu-Check
glucose meter. Afterwards, mice were anaesthetized using isoflur-
ane and plasma was collected by orbital puncture into EDTA-
coated tubes.
Amino acid analysis
For quantification of amino acids the targeted LC-MS/MS
approach with iTRAQH (AA45/32TM Phys REAG Kit, Applied
Biosystems, USA) was used as described previously [57]. For
measurement of tissue amino acids and derivatives (skeletal
muscle, liver, small intestine, kidney) small pieces of tissues were
homogenized in liquid nitrogen. 100 mg of grounded tissue were
dissolved in 150 ml MeOH/H2O (50:50 v/v), vortexed, and
centrifuged. Sample preparation was done according to the
manufacturer’s instructions using 40 ml of the supernatant of the
tissue homogenates or 40 ml plasma. Tissue amino acid concen-
trations were standardized with protein concentrations determined
via Bradford assay (Bio-Rad Laboratories GmbH, Germany).
Plasma amino acids of the STZ-trial were determined after
derivatization with aTRAQH (aTRAQTM Reagent Kit, ABSciex,
Foster City, USA). Sample preparation was done according to the
manufacturer’s instructions using 40 ml plasma.
Everted gut sacs
To determine the capacity of the intestine to convert arginine to
citrulline in vitro we used 13C15N-labeled arginine (labeling rate for
13C: 98%, and for 15N: 98%; Silantes GmbH, Germany) as a
substrate. The use of 13C15N-arginine (M=184.1 g/mol) enabled
to distinguish between citrulline (M=182.1 g/mol) produced via
ornithine and citrulline (M=184.1 g/mol) produced by nitric
oxide (NO) synthase. The whole small intestine was taken out,
mesenteric fat as well as the proximal 7 cm of small intestine were
removed. The tissue was then washed and rinsed with ice-cold
Krebs buffer (119 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2,
1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, and 1%
HEPES, pH 7.4) and everted. The intestine was cut into 2 cm
segments beginning at the proximal site. Per mouse, 2 to 4 sacs
were prepared and filled with Krebs buffer. Sacs were directly
incubated at 37uC for 30 min on a shaker in 2 ml Krebs buffer
solution containing 0.1 mM 13C15N-labeled arginine and 2 mM
glutamine, as glutamine was shown to enhance intestinal citrulline
production [58]. During the incubation Krebs buffer was
oxygenated with carbogen (5% CO2/95% O2). After incubation
tissues were washed with ice-cold Krebs buffer and serosal and
mucosal fluids were collected and stored at 280uC. The
concentrations of 13C15N-labeled arginine and its products
citrulline and ornithine were determined by iTRAQ-labeling
using 40 ml of the collected fluids. Intestinal ornithine and
citrulline release were standardized with protein concentrations
which were determined by Bradford assay after sacs were dried
over-night at and digested using 1 M NaOH at 37uC.
Statistical analysis
Results are presented as mean 6 SD or as fold-changes.
Statistical analysis was performed using the R software package
2.12 [59]. Tests for statistical significance were either done by two-
way ANOVA (diet6time interaction for HF study 1) following
pair-wise comparison with Tukey post-hoc test or by unpaired
Student’s t-test. Significance was assumed when p,0.05. Corre-
lation analysis was performed within the Hmisc package using the
function rcorr and Pearson method.
Supporting Information
Table S1 Plasma amino acid concentrations of study 1
over the time-course of 12 weeks HF feeding. Mice were
fed a C diet (10 energy% from fat, n = 12) or HF diet (45 energy%
from fat, n = 12) for 12 weeks and plasma was analyzed every
second week. Data displays all analyzed amino acids plus sum of
all amino acids.
(XLS)
Table S2 Plasma amino acid concentrations of study 2
after 12 weeks of HF feeding. Mice were fed a C diet (11
energy% from fat, n = 9) or HF diet (60 energy% from fat, n = 7)
Table 5. Nutrient composition of experimental diets used for
the HF feeding trials.
study 1 study 2
C HF C HF
Crude protein 200 200 208 241
Crude fat 45 202.5 42 340
Beef tallow - - - 310
Soybean oil 25 25 40 30
Palm oil 20 177.5 - -
Crude fiber 50 50 50 50
Starch 427.5 72.8 468 22
Sugar 172.8 172.8 108 224
Maltodextrine 100 100 - -
Dietary energy-%
carbohydrate
69 35 66 21
Dietary energy-%
protein
20 20 23 19
Dietary energy-% fat 10 45 11 60
Nutrient composition expressed as (g/kg) except not stated otherwise.
doi:10.1371/journal.pone.0063950.t005
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for 12 weeks. Data displays all analyzed amino acids plus sum of
all amino acids.
(XLS)
Table S3 Amino acid concentrations of the small
intestine after 12 weeks of HF feeding. Mice were fed a C
diet (11 energy% from fat, n = 9) or HF diet (60 energy% from fat,
n = 8) for 12 weeks. Data displays all analyzed amino acids plus
sum of all amino acids.
(XLS)
Table S4 Renal amino acid concentrations after 12
weeks of HF feeding.Mice were fed a C diet (11 energy% from
fat, n = 9) or HF diet (60 energy% from fat, n = 8) for 12 weeks.
Data displays all analyzed amino acids plus sum of all amino acids.
(XLS)
Table S5 Hepatic amino acid concentrations of study 1
after 12 weeks of HF feeding. Mice were fed a C diet (10
energy% from fat, n = 12) or HF diet (45 energy% from fat,
n = 12). Data displays all analyzed amino acids plus sum of all
amino acids.
(XLS)
Table S6 Hepatic amino acid concentrations of study 2
after 12 weeks of HF feeding. Mice were fed a C diet (11
energy% from fat, n = 9) or HF diet (60 energy% from fat, n = 8)
for 12 weeks. Data displays all analyzed amino acids plus sum of
all amino acids.
(XLS)
Table S7 Skeletal muscle amino acid concentrations
after 12 weeks of HF feeding. Mice were fed a C diet (11
energy% from fat, n = 9) or HF diet (60 energy% from fat, n = 8)
for 12 weeks. Data displays all analyzed amino acids plus sum of
all amino acids.
(XLS)
Table S8 Plasma amino acid concentrations of mice 5
days after STZ treatment. Mice received either a single
intraperitoneal injection of streptozotocin (STZ) (180 mg/kg
bodyweight) in 0.1 M citrate buffer or 0.1 M citrate buffer alone
(control group). Amino acids were assessed 5 days after injection.
Data displays all analyzed amino acids plus sum of all amino acids.
(XLS)
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